»Go to related Japanese page in JPubb

Loading

Press Releases by "Astellas Pharma Inc."


You may also like to check companies from Astellas Pharma Inc.'s related industry or location as follows: Pharmaceuticals, Tokyo

« Previous1234567Next »
1 - 50 of 326 for your search
Astellas and Medivation Announce Submission of Application for Marketing Approval of Enzalutamide, an Oral Androgen Receptor Inhibitor, in Japan
[ Pharmaceuticals | 2013-05-24]
ASTELLAS RECEIVES MARKETING AUTHORISATION FOR VESOMNITM FROM THE NETHERLANDS MEDICINES EVALUATION BOARD (pdf 103KB)
[ Pharmaceuticals | 2013-05-23]
AVEO and Astellas Announce Presentations of Tivozanib Clinical Data at 2013 American Society of Clinical Oncology Annual Meeting
[ Pharmaceuticals | 2013-05-16]
FDA APPROVES TARCEVA (ERLOTINIB) TABLETS AND COBAS EGFR MUTATION TEST FOR SPECIFIC TYPE OF LUNG CANCER
[ Pharmaceuticals | 2013-05-15]
Reshaping research framework to enhance the ability to generate innovative drugs
[ Pharmaceuticals | 2013-05-14]
Astellas Announces Issuance of Stock Acquisition Rights for Stock Option Scheme under Stock-Linked Compensation Plan (pdf 59KB)
[ Pharmaceuticals | 2013-05-13]
Astellas Announces Cancellation of Treasury Stock
[ Pharmaceuticals | 2013-05-13]
Astellas announces a3 (a-cube) selection results on public open innovation site, and start of international invitation for public participation in research
[ Pharmaceuticals | 2013-05-08]
Astellas and Drais Partner To Develop Third Astellas Compound through Tacurion
[ Pharmaceuticals | 2013-05-07]
AVEO and Astellas Report FDA Oncologic Drug Advisory Committee Votes Tivozanib Application Did Not Demonstrate Favorable Benefit-to-Risk Evaluation in Treatment of Advanced Renal Cell Carcinoma
[ Pharmaceuticals | 2013-05-07]
POSITIVE CHMP OPINION FOR XTANDI™ (ENZALUTAMIDE) IN ADVANCED PROSTATE CANCER1
[ Pharmaceuticals | 2013-04-30]
Astellas Announces Changes of Representative Directors, Directors and Corporate Auditors (pdf 81KB)
[ Pharmaceuticals | 2013-04-25]
New Hire Reinforces Global Compliance Structure
[ Pharmaceuticals | 2013-04-15]
Astellas and Johns Hopkins University researchers identify a novel action of quetiapine in the regulation of cell-cycle related p21/Cdkn1a gene expression in CD-1 mice ～Data Reported in U.S. Scientific Journal, Translational Psychiatry～
[ Pharmaceuticals | 2013-04-10]
Participation in "Global Health Innovative Technology Fund (GHIT Fund)"
[ Pharmaceuticals | 2013-04-08]
Astellas and Ambrx Initiate Collaboration for Discovery and Development of Next-Generation Antibody Drug Conjugates for Oncology
[ Pharmaceuticals | 2013-04-05]
Medivation and Astellas Provide Update on PREVAIL -Companies Announce Phase 3 PREVAIL Interim Analysis Expected to Occur in 2013-
[ Pharmaceuticals | 2013-04-02]
Approval in Japan for Treating Functional Dyspepsia with Acofide®
[ Pharmaceuticals | 2013-03-25]
Nagasaki University and Astellas Launch Collaborative Research for Screening New Anti-Dengue Virus Drugs for Neglected Tropical Diseases
[ Pharmaceuticals | 2013-03-21]
Tokyo Institute of Technology and Astellas Launch Collaborative Research for New Anti-Dengue Virus Drugs for Neglected Tropical Diseases
[ Pharmaceuticals | 2013-03-21]
Notice of Completion of Acquisition of Own Shares (Under the provision of its Articles of Incorporation in accordance with Article 165, paragraph 2 of the Companies Act)
[ Pharmaceuticals | 2013-03-18]
Submits Application for Marketing Approval of Ipragliflozin (ASP1941), SGLT2 Inhibitor for Treatment of Type 2 Diabetes, in Japan
[ Pharmaceuticals | 2013-03-13]
Astellas and Ambit to End Collaboration for Joint Development and Commercialization of FLT3 Kinase Inhibitors (pdf 54KB)
[ Pharmaceuticals | 2013-03-12]
Non-inferiority Observed in Phase III Clinical Trial of Seasonal Flu Vaccine ASP7374
[ Pharmaceuticals | 2013-03-11]
Astellas and UCB Launch Cimzia® (certolizumab pegol) in Japan for the treatment of adult patients with rheumatoid arthritis
[ Pharmaceuticals | 2013-03-07]
Astellas Voluntarily Adopts International Financial Reporting Standards (IFRS) (pdf 29KB)
[ Pharmaceuticals | 2013-02-28]
NEW CLASS OF TREATMENT NOW AVAILABLE FOR PATIENTS WITH OVERACTIVE BLADDER (pdf 74KB)
[ Pharmaceuticals | 2013-02-26]
Pasetocin® and Sawacillin®: Approval for Additional Indication for Helicobacter pylori Eradication by Triple Therapy with Proton Pump Inhibitors and either Clarithromycin or Metronidazole
[ Pharmaceuticals | 2013-02-21]
Astellas Submits Additional Indication Application for Hypnosedative, Dormicum® in Japan (pdf 26KB)
[ Pharmaceuticals | 2013-02-20]
Enzalutamide Data Presented at ASCO GU Symposium (pdf 77KB)
[ Pharmaceuticals | 2013-02-14]
AVEO and Astellas Report Final Overall Survival Results from TIVO-1
[ Pharmaceuticals | 2013-02-13]
Reorganization of Astellas' Global Management Structure
[ Pharmaceuticals | 2013-02-05]
Astellas Announces Acquisition of Own Shares (pdf 28KB)
[ Pharmaceuticals | 2013-02-01]
Astellas Announces Relocation of Global HQ building in Tokyo
[ Pharmaceuticals | 2013-02-01]
Enzalutamide Data to Be Presented at ASCO GU Symposium (pdf 90KB)
[ Pharmaceuticals | 2013-01-31]
AVEO and Astellas Announce Presentations of Tivozanib Clinical Data at 2013 ASCO Genitourinary Cancers Symposium
[ Pharmaceuticals | 2013-01-30]
FDA ACCEPTS SUPPLEMENTAL NEW DRUG APPLICATION FOR TARCEVA® (ERLOTINIB) TABLETS FOR GENETICALLY DISTINCT FORM OF ADVANCED LUNG CANCER
[ Pharmaceuticals | 2013-01-16]
NEW CLASS OF TREATMENT FOR OVERACTIVE BLADDER APPROVED IN EUROPE
[ Pharmaceuticals | 2013-01-11]
Astellas and Sanwa Launch "ARGAMATE® 89.29% Granule 5.6g" - Hyperkalemia Treatment
[ Pharmaceuticals | 2013-01-10]
Astellas and Sanwa Launch "ARGAMATE® 89.29% Granule 5.6g" - Hyperkalemia Treatment
[ Pharmaceuticals | 2013-01-10]
Astellas and UCB announce approval of Cimzia®(certolizumab pegol) in Japan for the treatment of adult patients with rheumatoid arthritis
[ Pharmaceuticals | 2012-12-25]
Approval for Manufacturing and Marketing of "Micamlo® Combination Tablets BP," an Antihypertensive Drug
[ Pharmaceuticals | 2012-12-21]
Astellas announces recruitment completion of phase 3 pivotal study of isavuconazole, an agent for the potential primary treatment of invasive and life-threatening fungal infections (pdf 30KB)
[ Pharmaceuticals | 2012-12-14]
Presentation Materials for Press Conference on December 12 (pdf 5,075KB)
[ Pharmaceuticals | 2012-12-13]
FibroGen and Astellas Announce Initiation of Phase 3 Trial of FG-4592/ASP1517 for Treatment of Anemia of Chronic Kidney Disease (pdf 66KB)
[ Pharmaceuticals | 2012-12-12]
Notice of Completion of Acquisition of Own Shares (pdf 26KB)
[ Pharmaceuticals | 2012-12-11]
Ambit and Astellas Announce Presentation of Results from Phase 2 ACE Study of Quizartinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia(AML) at the 54th Annual Meeting of the American Society of Hematology (pdf 96KB)
[ Pharmaceuticals | 2012-12-11]
Astellas and UMN announce Completion of Administration of Phase III Clinical Trials of Seasonal Flu Vaccine ASP7374
[ Pharmaceuticals | 2012-12-11]
Astellas Announces Acceptance of U.S. New Drug Application for Tacrolimus Extended Release Capsules (pdf 42KB)
[ Pharmaceuticals | 2012-12-05]
AVEO and Astellas Announce Initiation of Patient Enrollment in Phase 2 Trial of Tivozanib inCombination with Paclitaxel in Patients with Advanced Triple Negative Breast Cancer
[ Pharmaceuticals | 2012-12-04]
« Previous1234567Next »



You may also like to check companies from Astellas Pharma Inc.'s related industry or location as follows: Pharmaceuticals, Tokyo

Press Conferense Videos
Sharp and Semiconductor Energy Laboratory Jointly Develop New Oxide Semiconductor Technology That Will Revolutionize Displays Sharp and Semiconductor Energy Laboratory Jointly Develop New Oxide Semiconductor Technology That Will Revolutionize Displays
Sharp Corporation 2012/06/01
More Videos
Latest Press Release Search

Save favorite searches Hot keywords

Fukushima | power supply | cloud | solar
*NOTE: Recommended keywords shown above.
Your Most Recently Viewed Companies
Visit any of the company pages in JPubb, and your most recently viewed companies will automatically show up here.

Erase all This feature:ON How to use
Most Popular: Astellas Pharma Inc.
1. Astellas and Medivation Announce Submission of Application for Marketing Approval of Enzalutamide, an Oral Androgen Receptor Inhibitor, in Japan
2013/05/24
2. Astellas to Establish Sales Affiliate in Australia
2011/02/03
3. Contents of Stock Acquisition Rights (Stock Option Scheme as Stock-Linked Compensation Plan)
2012/07/05
Feed
Releases by Prefecture
Hokkaido | Aomori | Iwate | Miyagi | Akita | Yamagata | Fukushima

Ibaraki | Tochigi | Gunma | Saitama | Chiba | Tokyo | Kanagawa

Niigata | Toyama | Ishikawa | Fukui | Yamanashi | Nagano

Gifu | Shizuoka | Aichi | Mie

Shiga | Kyoto | Osaka | Hyogo | Nara | Wakayama

Tottori | Shimane | Okayama | Hiroshima | Yamaguchi

Tokushima | Kagawa | Ehime | Kochi

Fukuoka | Saga | Nagasaki | Kumamoto | Oita | Miyazaki | Kagoshima | Okinawa
Releases by Stock Exchange
TSE (Tokyo) All | TSE1 | TSE2 | Mothers

OSE (Osaka) All | OSE1 | OSE2 | JASDAQ Standard | JASDAQ Growth

NSE (Nagoya) All | NSE1 | NSE2 | Centrex | NSE-only

SSE (Sapporo) All | Ambitious | SSE-only

FSE (Fukuoka) All | Q-Board | FSE-only
Press Release Search
Company
Industry
Prefecture
Stock Exchange
Date
(yyyy/mm/dd)		 //～
//
Listed or Non-listed
*NOTE: Please input only items to be specified.
*NOTE: The "date" here means the one on which a press release is uploaded on this website. So it isn't necessarily the same as its official announcement date.
Company Search
Company
Industry
Prefecture
Stock Exchange
Listed or Non-listed
*NOTE: Please input only items to be specified.